Keytruda glioblastoma trials. Find archived Novocure press releases from 2007 until today. Readouts are also due this year in first-line glioblastoma, from the phase 3 Trident study, and from the phase 2 Panova-4 trial, evaluating a Tecentriq combo in first-line pancreatic cancer. Of them, 16 received pembrolizumab before their surgeries and 19 received the drug afterward. S. Russia has begun trials of a personalized mRNA cancer vaccine that detects tumor-specific mutations, creates a custom vaccine in 7 days, and is offered for free to melanoma patients—blending AI, immunotherapy, and state sponsorship. FDA OKs Keytruda with paclitaxel for PD-L1 positive, platinum-resistant ovarian, fallopian tube or peritoneal cancers, improving survival and delaying growth. Jan 19, 2025 · Keytruda is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nov 14, 2024 · The 2-THE-TOP trial showed improved survival with Temodar, TTFields and Keytruda in glioblastoma patients compared to controls. David Tran, they tested whether combining two therapies—Tumor Treating Fields (also known as Optune) and Keytruda (an immunotherapy)—could improve survival for newly diagnosed GBM patients. All patients had recurrent glioblastoma. The trial, which took place at seven medical centers throughout the U. Full prescribing information for Keytruda and Keytruda Qlex will be posted on Drugs@FDA. Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. Several clinical trials over the past decade in patients with newly diagnosed GBM have shown improvements in progression-free survival (PFS), although they have not shown significant improvement in overall survival (OS). ’s immuno-oncology star Keytruda, the checkpoint inhibitor is set for testing in glioblastoma as part of a combo with Agenus’ cancer vaccine Immunotherapy drug, Keytruda (Pembrolizumab), extends survival times in patients with brain cancer but these results are obtained only when it is used pre-surgery. The 2-THE-TOP trial enrolled patients with newly diagnosed glioblastoma. Read the latest Novocure press releases and Novocure news. . The trial was with just 35 randomised patients and involved 16 using the immunotherapy before and 19 using it after surgery. Tran, MD, PhD — chief of neuro-oncology and co-director of the USC Brain Tumor Center, part of Keck Medicine of USC — evaluated a combination of TTFields and the checkpoint inhibitor Keytruda in newly diagnosed glioblastoma patients. At 2 weeks to 24 months, pembrolizumab was given for up to 34 cycles. Feb 4, 2026 · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant With Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant With Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58). Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations. , evaluated 35 people with recurrent and surgically resectable glioblastoma — meaning the tumors could be removed by surgery. Visit the patient website. Jun 8, 2025 · In a new clinical trial, led by USC Norris member and Co-Director of the USC Brain Tumor Center Dr. In what could see another use added to Merck & Co. At week 1, concurrent radiotherapy and temozolomide were given. Biopsy-only patients demonstrated longer progression-free and overall survival, with a high objective response rate. Jun 3, 2025 · A newly published study led by David D. Trials in glioblastoma, pancreatic cancer, and ovarian cancer are underway, with engineered cells being further augmented with “logic gates” and “safety switches” to navigate the maze of normal tissues. TTFields was first approved in recurrent glioblastoma in 2011, then in first-line glioblastoma in 2015, and mesothelioma in 2019. Tran is the chief of the Division of Neuro-Oncology and co-director of the Brain Tumor Center at the University of Southern California. Review the glioblastoma treatment clinical trials on this list and use the filters to refine the results by age and location. Learn about KEYTRUDA® (pembrolizumab), an immunotherapy that works with your immune system to help fight certain cancers. fxxv9e, i2oxeh, zjdb, s0eg, cifqh, atfcs, ubw0o, nffm, s2z3, cethhf,